Maze Therapeutics prices upsized IPO at $16 per share, aiming to develop precision medicines

From GlobeNewswire: 2025-01-30 19:30:38

Maze Therapeutics, Inc. announced the pricing of its upsized initial public offering, offering 8,750,000 shares of common stock at $16.00 per share, with expected gross proceeds of $140.0 million. The offering, expected to close on February 3, 2025, will be managed by J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities. The company aims to develop precision medicines for renal, cardiovascular, and metabolic diseases, focusing on chronic kidney disease with lead programs MZE829 and MZE782. For more information, contact Jillian Connell for investors and Dan Budwick for media inquiries.



Read more at GlobeNewswire: Maze Therapeutics Announces Pricing of Upsized Initial